Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04363866|
Recruitment Status : Withdrawn (discontinued in favor of more promising directions that may benefit patients)
First Posted : April 27, 2020
Last Update Posted : October 29, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|COVID-19 SARS-CoV-2||Drug: Hydroxychloroquine Drug: Placebo||Phase 2|
A total of 40 participants are planned for enrollment. Those enrolled into this study will be randomized 1:1 to receive either hydroxychloroquine or placebo control.
Participants will receive their study intervention for 5 days, after which they will be considered off protocol- directed therapy and receive medical management of their disease according to institutional standards. Participants may be followed for up to 180 days from initiating protocol therapy for clinical outcome, after which they will discontinue study participation.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Double-blinded Study.|
|Official Title:||A Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19)|
|Estimated Study Start Date :||August 2020|
|Estimated Primary Completion Date :||March 2021|
|Estimated Study Completion Date :||September 2021|
400 mg bid (PO) Day 1, followed by 200 mg bid (PO) Day 2 through Day 5
Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
Placebo Comparator: Placebo
Placebo pill bid (PO) Day 1 through Day 5 of the treatment period
A placebo is a pill that looks like the study drug but has no real medicine in it.
- Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale [ Time Frame: Day 5 ]A 6-point ordinal scale ranging from "Death" to "Not hospitalized with full resumption of normal activities" is used to evaluate differences in the clinical status between participants that receive placebo vs hydroxychloroquine
- Number of Participants with Detectable SARS-CoV-2 Virus from Day 0 to Day 28 and at Day 5 [ Time Frame: Day 0 to Day 28 and at Day 5 ]Assess differences in SARS-CoV-2 viral shedding between participants that receive placebo vs hydroxychloroquine
- Toxicity of Study Drug Assessed by Incidence of Adverse Events [ Time Frame: Day 0 to Day 28 ]Assess by incidence of Grade 3, Grade 4, and Serious Adverse Events (AEs)
- Duration of Initial Hospitalization [ Time Frame: Day 0 to Day 28 ]Assess length of hospitalization
- Mortality During Follow-Up [ Time Frame: Day 0 to Day 28 ]Assess number of deaths during study follow-up
- Mortality During Initial Hospitalization [ Time Frame: Day 0 to Day 28 ]Assess number of deaths in the hospital during initial hospitalization
- Incidence of New Hospital Resource Utilization [ Time Frame: Day 0 to Day 28 ]Assessing utilization of hospital resources
- Duration of Hospital Resource Utilization [ Time Frame: Day 0 to Day 28 ]Assessing duration of hospital resource utilization
- Changes in Cytokine Profile [ Time Frame: Day 0 to Day 28 ]Provide preliminary characterization of differences in inflammatory response between participants that receive placebo vs hydroxychloroquine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Ability to understand and the willingness to sign a written informed consent document.
- Individuals aged ≥ 18 years of all races and ethnic groups.
- Must have documented positive test result for SARS-CoV-2 (COVID19), or high clinical suspicion for SARS-CoV-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest X-ray or CT scan), lack of alternative diagnosis, and history of exposure to a known case of SARS-CoV- 2 infection within the past 14 days
- Not receiving institutional therapy for treatment of SARS-CoV-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s).
Must meet at least one of the following clinical stratifications:
- Have at least 1 minor criterion per ATS criteria (refer to Appendix A), or
- Have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., X-ray or computed tomography [CT]), or
- High risk for poor outcome, as defined by any one of the following:
i. Age ≥ 60 years old ii. Underlying medical comorbidities, defined as:
- Serious cardiovascular disease
- Poorly controlled diabetes (i.e., A1c levels >7%)
- Chronic kidney disease requiring dialysis
- Significant liver disease (Pugh-Child B or C)
- Severe obesity (body mass index [BMI] ≥ 40)
- Chronic respiratory disease (e.g., COPD)
- Hypertension, defined as blood pressure ≥ 140 / 90 mmHg iii. Solid organ or stem cell transplant recipient iv. Diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. Receipt of biologic agent or prednisone > 0.5 mg/kg/day (or equivalent)
- Patient must be within 5 days of symptom onset, as determined by clinical team.
- Participants with preexisting auditory damage are allowed.
- Participants with a history of epilepsy are allowed.
- Female participants of childbearing potential (FOCBP) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug.
- FOCBP must agree to use highly-effective method(s) of contraception (Appendix B) during the study and for 1 months after the last dose of study drug. FOCBP are those who have not been surgically sterilized or have not been free from menses for >1 year without an alternative medical cause.
- Male participants must agree to use an adequate method of contraception (Appendix B) starting with the first dose of study therapy through at least 1 months after the last dose of study drug.
- Participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.
- The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
- Psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent.
- Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation >500 ms, electrolyte disturbances, etc.), or participants with congenital long QT syndrome
- Patients with Myesthenia Gravis or other neuromuscular disorders
Patients with history of psoriasis.
a. May be waived at the discretion of the PI
Patients with history of porphyria
a. May be waived at the discretion of the PI
- Concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the Principal Investigator
- Hypersensitivity to the study agent, or any of its excipients.
- Females who are pregnant or lactating.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04363866
|United States, Oregon|
|Oregon Health and Science University|
|Portland, Oregon, United States, 97239|
|Principal Investigator:||Marcel Curlin, MD||Oregon Health and Science University|
|Responsible Party:||Marcel Curlin, Principal Investigator, Oregon Health and Science University|
|Other Study ID Numbers:||
|First Posted:||April 27, 2020 Key Record Dates|
|Last Update Posted:||October 29, 2020|
|Last Verified:||October 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Individual participant data that underlie the results reported in this article, after the identification|
Statistical Analysis Plan (SAP)
|Time Frame:||Beginning 3 months and ending 5 years following article publication|
|Access Criteria:||Anyone who wishes to access the data for any purpose. Data may be obtained by contacting the corresponding author of the relevant publication|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases
Molecular Mechanisms of Pharmacological Action